Table 1.

Demographic and clinical features of the patients included in the study

Age (year)	13.8±4.0
Sex
Male	59% (n=11)
Female	41% (n=9)
Mutation statue
Homozygous	59% (n=13)
Compound heterozygous	27% (n=6)
Other	14% (n=3)
Years of disease (avg.)	5.1±2.6
Colchicine dose (mg/day) (avg.)	1.2±0.3
Total canakinumab number (avg.)	7.2±2.8
CRP (mg/dL) (avg.)
Before canakinumab	6.8±4.1
After canakinumab	0.4±0.6
SAA (mg/L) (avg.)
Before canakinumab	465.2±58
After canakinumab	5.1±2.6
Observation (month) (avg.)	15.9±8.8
Complete remission	100% (n=22)
Partial remission	0% (n=0)

Avg: average